Agenda Details | ASGCT Annual Meeting

Detailed Program

Tuesday, May 16 2023
08:00 AM – 12:00 PM PT

Immune Effector Cells: 2023 and Beyond!

With the goals of reflecting on the advances made over the past decade in adoptive cell therapy (ACT) based platforms, this session will 1) highlight novel advances in some of the earliest forms of ACT; 2) provide an overview of current landscape of CAR T-cells and 3) outline future directions for ACT in the next decade. Given the clear importance of ACT in cancer therapies and beyond, this session will energize and inform all those interested in learning more about the past, present, and future of immunotherapy.

Session Details

08:00 AM – 12:00 PM - Room 515 AB

Co-Chair

Daniel J.. Powell, Jr., PhD. University of Pennsylvania, Philadelphia, PA

08:00 AM – 12:00 PM - Room 515 AB

Co-Chair

Nirali Shah, MD, MHSc. National Cancer Institute, Bethesda, MD

08:01 AM – 08:20 AM - Room 515 AB

TILs in 2023: State of the Art and Future Directions

Stephanie Goff, MD. National Cancer Institute (NIH), MD

08:20 AM – 08:40 AM - Room 515 AB

TCR based strategies: State of the Art and Future Directions

Aude Chapuis, MD. Fred Hutchinson Cancer Research Center, Seattle, WA

08:40 AM – 09:00 AM - Room 515 AB

HSCT and Gene Editing to Optimize IEC Therapy

Saar Gill, MBBS, PhD, FRACP. University of Pennsylvania, Philadelphia, PA

09:00 AM – 09:15 AM - Room 515 AB

Panelist

Saar Gill, MBBS, PhD, FRACP. University of Pennsylvania, Philadelphia, PA

09:00 AM – 09:15 AM - Room 515 AB

Panelist

Aude Chapuis, MD. Fred Hutchinson Cancer Research Center, Seattle, WA

09:00 AM – 09:15 AM - Room 515 AB

Panelist

Stephanie L. Goff, MD. National Cancer Institute (NIH), Bethesda, MD

09:15 AM – 09:35 AM - Room 515 AB

GD2 Targeting and Midline Brainstem Tumors

Sneha Ramakrishna. Stanford University, CA

09:35 AM – 09:55 AM - Room 515 AB

CD19-palooza: Summary of indications and factors impacting outcomes

Michael D.. Jain. Moffitt Cancer Center, Tampa, FL

09:55 AM – 10:15 AM - Room 515 AB

BCMA CAR T-cells: Summary of Indications, Use and Outcomes in Multiple Myeloma

Yi Lin, M.D., Ph.D.. Mayo Clinic, MN

10:15 AM – 10:30 AM - Room 515 AB

Panelist

Sneha Ramakrishna. Stanford University, Palo Alto, CA

10:15 AM – 10:30 AM - Room 515 AB

Panelist

Michael D.. Jain. Moffitt Cancer Center, Tampa, FL

10:15 AM – 10:30 AM - Room 515 AB

Panelist

Yi Lin, M.D., Ph.D.. , MN

10:45 AM – 11:05 AM - Room 515 AB

Beyond T-cells: CAR-Macs, CAR-NKs

Michael Klichinsky, PharmD. Carisma Therapeutics, PA

11:05 AM – 11:25 AM - Room 515 AB

CD 19 CAR T-cells for SLE

Samik Basu, MD. Cabaletta Bio - Philadelphia, PA, Philadelphia, PA

11:25 AM – 11:45 AM - Room 515 AB

Harnessing synthetic biology and gene editing technologies to engineer next generation CAR T cells

Justin Eyquem, PhD. UCSF, CA

11:45 AM – 12:00 PM - Room 515 AB

Panelist

Samik Basu, His/Him. Cabaletta Bio - Philadelphia, PA, Philadelphia, PA

11:45 AM – 12:00 PM - Room 515 AB

Panelist

Michael Klichinsky. University of Pennsylvania, Philadelphia, PA

11:45 AM – 12:00 PM - Room 515 AB

Panelist

Justin Eyquem, PhD. UCSF, CA